We Will Cure

We are proud to share that Moffitt Cancer Center has been recognized in the 2026 Cure Innovation Index Ranking (@cure345). This national benchmark measures biomedical research institutions on their ability to drive translation from discovery to real-world impact. Learn more: bit.ly/4te0HGI

The newly released Cure Innovation Index reveals which U.S. research institutions actually turn biomedical science into patient impact. Of the select 303 institutions on the list, there are some that are outperforming their federal funding by a lot, in some cases by 100+ spots. They’re doing more with less. Better support for founders, closer industry ties, more intentional commercialization. See the list of 20 overperforming universities here: wewillcure.com/insights/innov…

We're excited to share that the inaugural Cure Innovation Index (@cure345) has ranked Gladstone 15th among the top 60 institutes and centers in the United States for our ability to translate scientific discovery into real-world healthcare impact. 🥳 🥂 bit.ly/3ORdH70

Top U.S. biomedical institutes (Cure Innovation Index): 1. Mass General Brigham 2. Mayo Clinic 3. Scripps Research Institute 4. Memorial Sloan Kettering Cancer Center 5. Dana-Farber Cancer Institute A new national index focused on translating discovery into real patient impact

@IcahnMountSinai was ranked as one of the Most Innovative Institutions by Cure Innovation Index, receiving the top ranking of any free-standing medical center and the top ranking in New York State.

We’re proud to share that we’ve been ranked #5 among 60 institutes and centers in the 2026 Cure (@cure345) Innovation Index Ranking—a national benchmark measuring how effectively U.S. biomedical research institutions turn discovery into real-world health impact. Learn more: bit.ly/3OUKAQb

The conditions that turn science into cures have never been measured systematically — until now. The Cure Innovation Index benchmarks what drives success in the top 303 U.S. institutions. #CureInnovationIndex, via @EurekAlert! eurekalert.org/news-releases/…

AI in healthcare is entering a new chapter. Pat McGloin, shared with @cure345 why #ChatGPT5 could transform patient engagement, health literacy, and access – particularly if we keep the human in the loop. 🔗okt.to/QDAPwl #DigitalHealth

🚨New Cure survey of 100+ healthcare CEOs + founders reveals: 87% remain optimistic about the future of biotech—despite funding dips + policy shifts. 📈 65% say access to capital is their top concern. 🔗 Read the full report: wewillcure.com/insights/healt… #Biotech #policyshifts #FutureOfHealth #HealthcareInnovation #Funding

Researchers are excited about detecting tumor DNA circulating in patients' blood before other markers of cancer appear, and its potential to direct treatment early. Read my article on this trend in @cure345: wewillcure.com/insights/oncol…

This morning, @xprize Executive Director, @j_n_justice and Cure CEO Seema Kumar kicked off the XPRIZE Healthspan Investor Summit. The event features semifinalist teams from the $101M XPRIZE Healthspan competition, 40 innovative organizations from around the globe, and leading investors in healthspan and longevity. The Summit provides opportunities for business leaders to get early access to groundbreaking investment opportunities presented by visionary innovators. #XPRIZEhealthspan #longevity #healthspan #investors

@Congratulations Dr. Randi Silver.

Register today: linkedin.com/video/event/ur…

🧠 FDA just cleared a wireless brain implant from @PrecisionNeuro_ in a new era for brain-computer interfaces (BCIs). 70+ clinical trials are testing BCI tech to restore movement, speech & mental health. 💥 $12B market incoming. 🔗 Read more: wewillcure.com/insights/medte… #Neurotech #FDA #DigitalHealth #BCI #BrainHealth @RS_Flinn

@Sunbird_Bio is transforming brain disease detection with would could be a first-of-its-kind blood test that identifies neurodegeneration before clinical symptoms appear, for diseases such as Alzheimer’s, #ALS & Parkinson’s. Read More: wewillcure.com/insights/neuro… #braindiseases

🚨 New Trump-era tariffs are straining equipment costs for hospitals and research labs. 📊 Surveys show the fallout will be far-reaching. “The second wave of tariffs is no longer a theoretical threat—it’s a full-blown disruption,” says @blackbookpolls' Doug Brown. So, what’s next for hospitals, patients and science? Read more from Cure writer @RS_Flinn wewillcure.com/insights/medte…

Gene and cell therapies are 2x more likely to win FDA approval, but most still aren’t reaching patients. A new @Nature Reviews Drug Discovery study reveals why—cost, infrastructure & delivery gaps. Since 2017, 30+ therapies approved. Read More: wewillcure.com/insights/news/… #genetherapy #FDAApproval

🚨 A new report from the bipartisan @NSCbiotech warns that the U.S. is falling behind China in biotech and calls for a $15B investment to protect our leadership in innovation, health, and security. 🧬 Read more by Cure writer @RS_Flinn : wewillcure.com/insights/inves… #Biotech #HealthInnovation #NatSec #FutureOfHealth #USvsChina

wewillcure.com/insights/medte… While biotech struggled, one category surged: AI-driven startups. @isomorphiclabs raised $600M—led by @thrivecapital with @GVteam & @Alphabet—to push AI drug discovery into the clinic. Read more from Cure writer @RS_Flinn, who explains how #AImoonshots are reshaping biotech funding.

wewillcure.com/insights/entre… "I'm deeply concerned by some of what has happened in recent weeks in terms of the cuts to science and research funding, particularly from my perspective in the #biomedical research domain. I fear that we are really undermining and dismantling critical and exciting areas of research that will provide us the treatments, cures, and prevention strategies that we need," says former #FDA Commissioner Margaret Hamburg, MD. Read more in our exclusive interview with Dr. Hamburg, who discusses the impact of #federallayoffs and healthcare in an era of uncertainty.